Hang sells NVS 88.53: Alzheimer's Rates Falling, But Pharma's Search For a Cure Yields No Results
Earlier this week, Novartis (NYSE: NVS) announced that, pending regulaory approval, it plans a study in Europe and North America starting next year, to see if two of its drugs can prevent the disease in people who have a genetic risk of developing Alzheime ... ...
20 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home